Projekt

Novel screening assay for novel psychoactive substances

Geplant · 2024 bis 2025

Art
Grundlagenforschung
Bereiche
Status
Geplant
Start
2024
Ende
2025
Finanzierungsart
Fördermittel KSSG
Kurzbeschreibung/Zielsetzung

Consumption of so-called novel psychoactive substances (e.g. “synthetic opioids” and “synthetic cannabinoids”) is a growing global health threat. Due to the rapid market dynamics of the new drugs of abuse market current analytical methods cannot keep up and detection of an uptake of these compounds remains challenging, time-consuming and expensive. Consequently, novel analytical approaches are necessary to fill the gap and prevent that intoxications and deaths due to these compounds go undetected. The here presented project aims at the development of a new approach for the detection of drug uptake in biological samples. Following a new concept by choosing the binding at the dedicated receptor of e.g. synthetic cannabinoids (CB1) rather than analyzing for the compound itself as the analytical target. This opens the opportunity to have a chemical-structure independent and thus futureproof screening method for e.g. clinical and forensic laboratories available.